Skip to content
Open access

Circulating immune biomarkers indicate patients' immune imbalance and predict their disease severity and poor prognosis in pulmonary tuberculosis.

Oct 2026 · Infection · 0 citations · 37 references
Medicine

Abstract

Background

A comprehensive understanding of the host immune response and identifying valuable markers to predict disease severity and patient's prognosis is a crucial issue.

Methods

Plasma levels of 12 soluble immune checkpoints (sICPs), 12 cytokines/chemokines and blood immune cell subsets were analyzed through flow cytometry.

Results

Seven sICPs, such as sCD25 (P < 0.001), sCD27 (P < 0.001), sPD-L1 (P < 0.001), sPD-L2 (P = 0.031), sTim-3 (P < 0.001), sLAG-3 (P = 0.003), sGal-9 (P < 0.001) were positively correlated with disease severity in pulmonary tuberculosis (PTB) patients (n = 78). Four cytokines/chemokines, such as IL-6 (P < 0.001), IL-8 (P < 0.01), IP-10 (P < 0.001) and IFN-γ (P < 0.01), and some routine laboratory examinations, such as absolute neutrophil count (Neutrophil, P < 0.001), were also significantly elevated in severe PTB (SE). However, absolute lymphocyte count (LY, P < 0.001) was significantly lower in SE patients. Through Lasso regression analysis, six factors, including sCD25,sTim-3,IP-10, LY, Neutrophil, lactic dehydrogenase (LDH) were screened and weighted to form the Immune Imbalance Score (IIS). Patients with higher IIS had higher possibility to experience severe illness (P < 0.001) and shorter survival time (P < 0.001). Furthermore, the result of blood immune cell revealed that the frequencies of exhausted CD8 + T cells (Tim-3 + CD8+T cells, n = 48, P = 0.037) were significantly increased in SE patients than those in non-SE patients.

Conclusion

Patients with severe PTB exhibited a high inflammatory status, but their lymphocytes decreased and CD8 + T cells showed exhaustion. Patients' IIS could potentially serve as biomarkers to predict PTB patients' disease severity and prognosis.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.